π€ Oncology Research - VERITAC-2 Trial Results
This article summarizes the primary results of the VERITAC-2 clinical trial, comparing vepdegestrant to fulvestrant in ER+/HER2β metastatic breast cancer patients post-CDK4/6i. The focus is on progression-free survival (PFS) and objective response rate (ORR).
Key Points:
β’ Significant PFS improvement observed in ESR1-mut+ patients with vepdegestrant.
β’ No statistically significant difference in PFS observed in the ITT population.
β’ Higher ORR observed in ESR1-mut+ patients treated with vepdegestrant.
π Resources:
β’ Larvol β - Oncology expert
β’ SuyogCancer β - Oncology researcher
Image
Image
Image
π€ Oncology Research - DESTINY-Gastric04 Trial Results
This article presents a summary of the DESTINY-Gastric04 trial comparing T-DXd to ramucirumab+paclitaxel in patients with HER2+ gastroesophageal junction or gastric adenocarcinoma. Key findings regarding overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) are highlighted.
Key Points:
β’ T-DXd demonstrated a statistically significant improvement in overall survival.
β’ A modest improvement in progression-free survival was observed with T-DXd.
β’ Higher objective response rate was seen in the T-DXd arm.
π Resources:
β’ Larvol β - Oncology expert
β’ SuyogCancer β - Oncology researcher
Image
Image
Image
Image
π€ Oncology Research - INAVO120 Trial Results
This article summarizes the results of the INAVO120 trial, evaluating a triplet combination therapy (inavolisib + palbociclib + fulvestrant) in patients with PIK3CA-mutant, HR+/HER2β advanced breast cancer. The key findings focus on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).
Key Points:
β’ Statistically significant improvement in overall survival observed with the triplet regimen.
β’ Marked improvement in progression-free survival seen with the triplet therapy.
β’ Substantially higher objective response rate achieved with the triplet regimen.
π Resources:
β’ Larvol β - Oncology expert
β’ SuyogCancer β - Oncology researcher
Image
Image
Image
Image
π€ AI in Oncology - Massive Bio at ASCO 2025
This article briefly describes Massive Bio's presence and activities at the ASCO 2025 conference, focusing on their contributions to oncology through AI-powered solutions.
Key Points:
β’ Advancement of oncology through AI-powered clinical trial matching.
β’ Contribution to oncology through real-world data solutions.
β’ Focus on collaborative intelligence in oncology research.
π Resources:
β’ MassiveBio β - AI solutions for oncology
β’ ASCO β - American Society of Clinical Oncology
Image
π Medical Technology - Butterfly iQ Ultrasound Discount
This article announces a limited-time discount on Butterfly iQ3 and iQ+ ultrasound devices for students and residents.
Key Points:
β’ Discounted pricing for Butterfly iQ3 and iQ+.
β’ Limited-time offer for students and residents.
π Resources:
β’ Butterfly Network β - Ultrasound device
Image
π€ AI in Global Health - Qure.ai at WHA78
This article summarizes Qure.ai's participation in a panel discussion at the 78th World Health Assembly (WHA78) on leveraging AI to improve efficiency and impact in global health.
Key Points:
β’ Focus on maximizing the impact of investments in health systems.
β’ Panel discussion on using AI to achieve "more with less" in global health.
β’ Collaboration between Ministries of Health, global funders, NGOs, and the private sector.
π Resources:
β’ Qure.ai β - AI solutions for healthcare
Image
π€ AI in Healthcare - Rad AI at RSNA
This article highlights the impact of AI in healthcare as perceived by Rad AI's Lead Product Manager, Chris Walker, following his experience at RSNA.
Key Points:
β’ AI's impact in healthcare is no longer theoretical but is happening at scale.
π Resources:
β’ Rad AI β - AI solutions for radiology
Image
π€ AI in Mental Healthcare - Spectruth DAO x AxonDAO
This article announces a collaboration between Spectruth DAO and AxonDAO to provide real-time AI support for mental healthcare, focusing on PTSD.
Key Points:
β’ Commitment to bringing precision mental health care to everyone.
β’ Focus on those most at risk for PTSD.
β’ Collaboration between Spectruth DAO and AxonDAO.
π Resources:
β’ Spectruth AI β - AI for mental health
β’ AxonDAO β - Decentralized autonomous organization focused on mental health
π€ Oncology Research - HER2DX Prognostic Value in Early Breast Cancer
This article discusses a study presented at ASCO 2025 on the prognostic value of HER2DX in older patients with HER2-positive early breast cancer.
Key Points:
β’ Study on HER2DX prognostic value in older patients with HER2-positive early breast cancer.
β’ Data from the RESPECT phase III trial.
β’ Collaboration with Prof. Aleix Prat and REVEAL GENOMICS.
π Resources:
β’ Larvol β - Oncology expert
β’ Kazuki Nozawa β - Researcher
β’ Reveal Genomics β - Genomics research
Image
π€ AI in Lung Cancer Care - Qure.ai in Goa, India
This article describes Goa, India's implementation of AI-powered lung cancer screening at a statewide scale.
Key Points:
β’ Goa is the first state in India to deploy AI-powered lung cancer screening statewide.
β’ Use of AI in pioneering lung cancer care.
π Resources:
β’ Qure.ai β - AI solutions for healthcare
β’ Visrane β - Healthcare technology company
Image
Image
βοΈ Support
If you liked reading this report, please star βοΈ this repository and follow me on Github β, π (previously known as Twitter) β to help others discover these resources and regular updates.
